-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 23, CanSino Bio announced on the Hong Kong Stock Exchange that the company cooperated with the Institute of Biological Engineering of the Academy of Military Sciences of the Chinese People’s Liberation Army on March 22 to develop a recombinant new coronavirus vaccine for inhalation (adenovirus type 5).
It is reported that the vaccine is the first approved adenovirus vector new crown vaccine in China.
According to relevant media reports, CanSino Bio has previously emphasized that according to the interim data of the global multi-center phase III clinical trial, there has been no serious adverse reaction related to the vaccine.